Viveve Medical (Viveve Medical) Risk Assessment

View and export this data going back to 2016. Start your Free Trial

What is Viveve Medical Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Viveve Medical is: No Data: Cannot be evaluated.

Competitive Comparison of Viveve Medical's Risk Assessment

For the Medical Devices subindustry, Viveve Medical's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viveve Medical's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Viveve Medical's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Viveve Medical's Risk Assessment falls into.

Viveve Medical (OTCPK:VIVE) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Viveve Medical Risk Assessment Related Terms

Thank you for viewing the detailed overview of Viveve Medical's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Viveve Medical (Viveve Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Viveve Medical Inc (OTCPK:VIVE) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

345 Inverness Drive South, Building B, Suite 250, Englewood, CO, USA, 80112

Website

https://www.viveve.com

Viveve Medical Inc designs, develops, manufactures and markets a platform medical technology. Its Cryogen-cooled Monopolar Radiofrequency technology is delivered through a radiofrequency generator, handpiece and treatment tip, called the Viveve System. The Viveve System is for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The Viveve System is indicated for use and being marketed for use in general surgical procedures for electrocoagulation and hemostasis in the United States. It has a business presence in the US, Asia Pacific, Canada, Europe and Middle East and Latin America.

Executives

Presnell Sharon Collins	director	6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Goldman Sachs Group Inc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Wilmot B. Harkey	10 percent owner	C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Daniel Mack	10 percent owner	C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Nantahala Capital Management, Llc	10 percent owner	130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Karen L. Zaderej	director	AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Steven L Basta	director	1875 S GRANT STREET SUITE 110, SAN MATEO CA 94402
Scott Durbin	officer: Chief Financial Officer	PO BOX 376, ANN ARBOR MI 48106
James G. Atkinson	officer: CBO & President	150 COMMERCIAL STREET, SUNNYVALE CA 94086
Patricia Scheller	director, officer: CEO and Director	150 COMMERCIAL STREET, SUNNYVALE CA 94086
Jon M Plexico	director, 10 percent owner	16430 N SCOTTSDALE RD 450, SCOTTSDALE AZ 85254
Stonepine Capital Management, Llc	director, 10 percent owner	919 NW BOND STREET, SUITE 204, BEND OR 97703
Timothy P Lynch	director, 10 percent owner	919 NW BOND STREET, SUITE 204, BEND OR 97703
Daniel Janney	director, 10 percent owner	PO BOX 7414, JACKSON WY 83002